At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 300 enrolled
Drug / intervention
botulinum toxin +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines
In Brief
A Phase 3 clinical trial evaluating botulinum toxin and Placebo for Glabellar Frown Lines. Completed, enrolled 300 participants across 14 sites in 2 countries.
Detailed Summary
The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe GL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Frown Lines
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartFeb 2020
Primary CompletionAug 2020
Study CompletionJan 2021
TodayJul 2026
First PostedJan 31, 2020
Enrollment StartFeb 10, 2020
Primary CompletionAug 7, 2020
Study CompletionJan 5, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.4 years ago
Interventions
botulinum toxinbiological
neuromodulator to be injected in the GL region
Placebobiological
Placebo to be injected in the GL area